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Abstract
Leucine activates the intracellular mammalian target of the rapamycin (mTOR) pathway, and hypothalamic mTOR
signaling regulates food intake. Although central infusion of leucine reduces food intake, it is still uncertain whether
oral leucine supplementation is able to affect the hypothalamic circuits that control energy balance. We observed
increased phosphorylation of p70s6k in the mouse hypothalamus after an acute oral gavage of leucine. We then
assessed whether acute oral gavage of leucine induces the activation of neurons in several hypothalamic nuclei and
in the brainstem. Leucine did not induce the expression of Fos in hypothalamic nuclei, but it increased the number of
Fos-immunoreactive neurons in the area postrema. In addition, oral gavage of leucine acutely increased the 24 h
food intake of mice. Nonetheless, chronic leucine supplementation in the drinking water did not change the food
intake and the weight gain of ob/ob mice and of wild-type mice consuming a low- or a high-fat diet. We assessed the
hypothalamic gene expression and observed that leucine supplementation increased the expression of enzymes
(BCAT1, BCAT2 and BCKDK) that metabolize branched-chain amino acids. Despite these effects, leucine
supplementation did not induce an anorectic pattern of gene expression in the hypothalamus. In conclusion, our data
show that the brain is able to sense oral leucine intake. However, the food intake is not modified by chronic oral
leucine supplementation. These results question the possible efficacy of leucine supplementation as an appetite
suppressant to treat obesity.
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Introduction
The regulation of the energy balance and food intake relies
on the ability of the central nervous system (CNS) to receive
and process information about the nutritional status of the
organism. This information is conveyed by hormones, such as
leptin, insulin and ghrelin. In addition, variations in the
circulating levels of nutrients also convey important information
to the CNS about the fed/fasting state [1,2]. It has long been
known that specific populations of neurons can sense glucose
levels. Glucose-sensing neurons play a key role in the control
of glucose homeostasis, energy balance and counterregulatory
responses to hypoglycemia [3-5]. There have also been reports
indicating that the brain has a lipid-sensing ability that is critical
for the control of energy balance and insulin sensitivity [6,7].
However, despite the fact that amino acids are indispensable
macronutrients as substrates for the synthesis of proteins and
other molecules, much less is known about the ability of the
brain to sense their circulating levels. In fact, the body seems
to detect variations in the concentrations of amino acids
because systemic administration of amino acids can stimulate
whole-body protein synthesis [8,9]. Among all amino acids, it
appears that the branched-chain amino acid (BCAA) leucine is
of particular importance in conveying the level of amino acid
availability to cells because leucine is the most potent amino
acid that activates the mammalian target of the rapamycin
(mTOR) intracellular signaling pathway, which is critical for
initiating the protein translation process [10-16].
The availability of leucine has effects beyond the control of
protein synthesis, and some studies have also demonstrated
that supplementation with leucine induces changes in energy
balance and adiposity. Thus, it has been speculated that
leucine supplementation could be used for the treatment and
prevention of obesity [17,18]. However, previously obtained
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results have been controversial. Leucine supplementation
decreases adiposity in food-restricted rats [19] and during
aging [20]. However, while some studies have shown that
leucine supplementation reduces diet-induced obesity in
rodents [21-25], others did not find any significant effects on
adiposity with leucine supplementation [26,27]. In humans, the
combined supplementation of leucine and pyridoxine (vitamin
B6) increased the fat oxidation of overweight subjects [28].
However, 3 months of leucine supplementation did not change
the weight, the body composition and the energy intake and
macronutrient composition, calculated from the dietary intake
records, of healthy elderly men [29].
It is unclear how leucine is able to influence the energy
balance. Cota et al. [30] showed that hypothalamic mTOR
signaling regulates food intake. As leucine is a natural activator
of the mTOR signaling pathway, it is plausible to hypothesize
that leucine supplementation recruits mTOR signaling in the
hypothalamus, which in turn causes a reduction in food intake.
However, the vast majority of the studies that assessed the
consequences of leucine supplementation did not find any
reduction in food intake, even those studies that observed
decreases in body fat mass [19-21,24-27,31-37]. On the other
hand, when leucine is directly administered in the CNS through
an intracerebroventricular (i.c.v.) cannula, it does indeed cause
a reduction in food intake [22,30,38,39]. Considering that oral,
instead of central, administration of leucine is the only feasible
and physiological way to supplement leucine in people, it is
imperative to clarify whether oral leucine supplementation is in
fact able to affect hypothalamic circuitries that regulate food
intake. Therefore, the objective of the present study was to
employ acute and chronic paradigms of oral leucine
supplementation to assess possible changes in food intake and
activation of hypothalamic components that control energy
balance.
Results
Experiment 1
Acute oral administration of leucine induces
phosphorylation of p70S6K in the hypothalamus.   Acute
oral administration of leucine causes activation of p70S6K in
the skeletal muscle [10,11], the liver [12,40] and white adipose
tissue [14,41]. In the hypothalamus, p70S6K phosphorylation
can be induced by i.c.v. administration of leucine [22,30].
However, it is still uncertain whether orally administered leucine
is able to recruit this signaling pathway in the hypothalamus.
We observed that orally administered leucine increased the
phosphorylation of p70S6K in the hypothalamus of mice
(Figure 1).
Experiment 2
Acute oral administration of leucine induces the
expression of Fos protein in the area postrema.   The
expression of Fos protein is a well-established acute marker of
activated neurons [42]. Therefore, we assessed whether oral
leucine administration is able to activate neurons in several
nuclei of the hypothalamus and brainstem related to the
regulation of the energy balance (Table 1). In the
hypothalamus, the number of neurons expressing Fos-
immunoreactivity (Fos-ir) in the paraventricular nucleus of the
hypothalamus (PVH, Figure 2A-B), the arcuate nucleus of the
hypothalamus (ARH, Figure 2C-D), the ventromedial nucleus of
the hypothalamus (VMH, Figure 2C-D), the lateral
hypothalamic area (LHA, Figure 2C-D) and the dorsomedial
nucleus of the hypothalamus (DMH, Figure 2C-D) were similar
between the leucine and control groups (Table 1). In the
brainstem, we observed that the area postrema (AP) of
leucine-treated mice showed a higher number of Fos-
expressing neurons than the control group (Figure 2E-F and
Table 1). No difference in the expression of Fos-ir in the
nucleus of the solitary tract (NTS) was observed between
groups (Figure 2E-F and Table 1).
Experiment 3
Oral administration of leucine acutely increased the food
intake of mice.  The previous results suggested that the brain
is responsive to oral leucine supplementation. To determine
whether acute oral administration of leucine produces changes
in the food intake we daily habituated 20 single-housed mice to
receive 0.5 mL of water through gavage for one week. Latter,
mice received a gavage containing leucine for two days. Their
food intake and weight gain were compared to that observed
after receiving only water. Surprisingly, we observed an
increased food intake in the days when the mice received
leucine in comparison with the control (water) days (Figure 3A).
No changes in the weight gain (data not shown) or body weight
(Figure 3B) were observed among the studied days.
Experiment 4
Chronic leucine supplementation in the drinking water
does not change the food intake of genetically obese
(ob/ob) mice.   We assessed the food and water intake of
ob/ob mice for 20 days. In the first 10 days, the mice received
water to drink. In the remaining days, they were supplemented
with leucine in the drinking water. Each mouse acted as its own
control by comparing their food and water intake before and
during the supplementation period. The food intake of ob/ob
mice remained unaltered during the supplementation period
compared to the food intake assessed when the mice received
only water to drink (Figure 4A-B). Water intake also was not
affected by leucine supplementation (Figure 4C). Similarly,
weight gain was not influenced by leucine supplementation
(Control: 0.28 ± 0.02 g/day; Leucine: 0.27 ± 0.03 g/day; P =
0.7273). Based on the amount of leucine obtained through the
diet and water, total leucine intake during the supplementation
period was 2.7-fold (0.32 ± 0.01 g/day) higher than the basal
period (0.12 ± 0.01 g/day).
Experiment 5
Chronic leucine supplementation in the drinking water
does not change the food intake of wild-type mice
receiving a low- or a high-fat diet.   Now we decided to study
the effects of leucine supplementation in the drinking water of
wild-type mice receiving either a low- or a high-fat diet (HFD).
Initially, a group of mice received a HFD for 2 months while
another group was kept in their regular low-fat diet. Then, half
Oral Leucine Does Not Induce Anorectic Behavior
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of the mice in each group received leucine supplementation in
the drinking water for 6 weeks, whereas the other half had
water to drink. The consumption of the HFD caused a marked
increase in the body weight (Figure 5A) and adiposity (Figure
5B-C) compared to mice consuming the regular low-fat diet.
Oral leucine supplementation did not change the body weight
Figure 1.  Acute oral leucine administration induced phosphorylation of p70S6K in the hypothalamus.  Bar graphs showing
the quantification of the phosphorylation of p70S6K in the hypothalamus of mice that received oral gavage of water (CON group, n =
9) or leucine solution (LEU group, n = 9). The data were normalized to the expression of α-actinin. *, significantly different (P < 0.05)
from the CON group.
doi: 10.1371/journal.pone.0084094.g001
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of mice receiving either a low- or a high-fat diet (Figure 5A). In
accordance, no changes in the mass of subcutaneous,
perigonadal and retroperitoneal fat pads were observed
between control and leucine groups (Figure 5B-C). We
assessed the food intake all over the experiment and we failed
to find significant differences in the calorie intake comparing
control and leucine groups in both diets (Figure 5 D-E,G-H).
Water intake remained unchanged in leucine-supplemented
mice consuming a low-fat diet (Figure 5F). However, leucine
supplementation in the drinking water reduced the amount of
liquid ingested by mice consuming the HFD (Figure 5I). We
assessed serum corticosterone levels to determine whether
chronic leucine supplementation in the drinking water caused a
stress response (Figure S1). No changes were observed
between control and leucine groups, either in mice consuming
low- or high-fat diets (Figure S1). In addition, corticosterone
levels were 4 to 7 fold lower in mice of the control and leucine
groups compared to animals that were subjected to conditions
that increase corticosterone secretion such as psychosocial
stress or prolonged fasting (Figure S1). For the mice
consuming the low-fat diet, leucine supplementation in the
drinking water increased total leucine intake 3-fold (0.23 ± 0.01
g/day) compared to the control group (0.08 ± 0.00 g/day). In
the mice consuming the HFD, leucine intake increased
approximately 2.3-fold in the supplemented group (0.10 ± 0.00
g/day) compared to the control HFD group (0.05 ± 0.00 g/day).
Lack of evidence that leucine supplementation induces an
anorectic pattern of gene expression in the hypothalamus,
despite significant effects on the expression of enzymes that
metabolize BCAA
The mice from the previous experiment were euthanized,
and their hypothalami collected for gene expression analysis.
Initially, we assessed whether leucine supplementation in the
drinking water was able to affect the expression of genes that
encode the enzymes that metabolize the BCAA. The BCAT1
gene, which encodes the cytosolic form of the enzyme
branched-chain amino acid transaminase and is highly
Table 1. Number of neurons expressing Fos
immunoreactivity in nuclei of the hypothalamus and
brainstem of mice from control and leucine groups (n = 9-10
per group).
Area Control Group Leucine Group P
PVH 6.1 ± 1.6 8.0 ± 1.4 0.3913
ARH 9.4 ± 2.2 9.9 ± 2.4 0.8806
VMH 10.4 ± 2.2 12.8 ± 2.3 0.4669
LHA 24.9 ± 3.3 23.7 ± 2.7 0.7811
DMH 22.8 ± 1.4 18.8 ± 3.9 0.3246
NTS 3.7 ± 0.8 3.4 ± 0.8 0.8216
AP 1.5 ± 0.4 11.6 ± 2.6* 0.0008
* significantly different (P < 0.05) from control group (Student’s t-test). AP, area
postrema; ARH, arcuate nucleus of the hypothalamus; DMH, dorsomedial nucleus
of the hypothalamus; LHA, lateral hypothalamic area; NTS, nucleus of the solitary
tract; PVH, paraventricular nucleus of the hypothalamus; VMH, ventromedial
nucleus of the hypothalamus.
doi: 10.1371/journal.pone.0084094.t001
expressed in the brain [43], and the BCAT2 gene, which
encodes the mitochondrial form of the enzyme branched-chain
amino acid transaminase, showed no changes in mice
consuming a low-fat diet, but a higher expression in leucine-
supplemented animals consuming the HFD (Figure 6A-B). The
branched-chain α-ketoacid dehydrogenase complex (BCKDK)
showed an increased expression in the leucine-supplemented
groups, regardless of diet (Figure 6A-B).
Previous studies have demonstrated that central leucine
administration causes a rapamycin-dependent anorectic
behavior, possibly through its influence on the hypothalamic
circuitry that regulates energy balance [22,30,38,39,44].
However, much less is known about how chronic oral leucine
supplementation can affect the pattern of gene expression in
the hypothalamus. Therefore, we assessed the expression of
several genes involved in the regulation of food intake. Chronic
leucine supplementation in mice consuming the HFD caused
an increased mRNA expression of the neuropeptide Y (NPY)
and corticotropin-releasing hormone (CRH, Figure 6B). No
changes in mRNA expression of pro-opiomelanocortin (POMC)
and melanin-concentrating hormone (MCH) were observed
with leucine treatment (Figure 6A-B).
Discussion
Leucine supplementation has received special attention
because of its possible effects on the regulation of energy
balance and food intake [13,17,18,30]. Herein, we studied
chronic oral supplementation of leucine in genetically obese
mice and in wild-type mice receiving either low- or high-fat
diets. Overall, we failed to observe any significant reduction on
food intake or in the induction of an anorectic pattern of gene
expression in the hypothalamus. However, in an acute
paradigm of leucine supplementation, leucine seems to
increase food intake. In addition, we collected several pieces of
evidence showing that the brain is in fact able to sense the
increased ingestion of leucine, by increasing the hypothalamic
phosphorylation of p70S6K and the activation of neurons in the
AP, and by changing the expression of several genes in the
hypothalamus.
Our group and others have studied leucine supplementation
in rodents in distinct metabolic situations, such as food
restriction [19,31,32], aging [13,20,34,45,46], protein-restricted
diets [33,47], high-caloric diets [21-27,35,37,48,49] and
genetically obese models [22,50]. In the vast majority of these
studies, oral leucine supplementation, provided either in the
diet or in the drinking water, caused no changes in food intake
[13,14,19-21,24-27,31-37,45-50], although there are
exceptions [22,23,38,51]. In contrast, studies that aimed to
assess possible effects of leucine on the CNS and therefore
infused leucine directly into the brain have consistently shown
reductions in food intake [22,30,38,39,44]. Why, then, does oral
leucine supplementation usually result in different effects on
regulation of food intake compared to centrally injected
leucine? By infusing leucine directly into the brain, it bypasses
the blood-brain barrier and other “natural filters” (i.e., glia cells,
tanycytes, etc.) that protect the brain from toxic agents or
strong variations in substances in the blood. Therefore, it is not
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Figure 2.  Acute oral leucine increased the expression of Fos in the area postrema.  A-F. Brightfield photomicrographs of
mouse brain sections showing the Fos immunoreactivity (Fos-ir) in the paraventricular nucleus of the hypothalamus (PVH; A-B), the
mediobasal hypothalamus (C-D), the nucleus of the solitary tract (NTS; E-F) and the area postrema (AP; E-F) of mice from control
group (A, C, E; n = 10) and leucine group (B, D, F; n = 9). Arrowheads indicate neurons expressing Fos-ir in the AP. The boxes
shown in E and F exhibit a higher magnification image in the AP. Abbreviations: 3v, third ventricle; ARH, arcuate nucleus of the
hypothalamus; cc, central channel; DMH, dorsomedial nucleus of the hypothalamus; f, fornix; LHA, lateral hypothalamic area; VMH,
ventromedial nucleus of the hypothalamus. Scale Bar: A-B = 50 µm; C-D = 100 µm; E-F = 50 µm (higher magnification boxes = 25
µm).
doi: 10.1371/journal.pone.0084094.g002
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surprising that central leucine administration produces a much
stronger effect on brain function compared to paradigms that
provide leucine through the diet or drinking water. However, the
fact that oral leucine supplementation in most of the studies
cannot recapitulate the reduction in food intake observed after
centrally infused leucine suggests that these presumable
effects of leucine must be revised or examined with caution. It
is important to consider that if leucine becomes a therapeutic
supplement to treat obesity or other diseases in human beings,
just as it has been tested [28], leucine would be provided in an
oral form. Therefore, it would be more useful for future studies
that assess the effects of leucine on the regulation of food
intake focus primarily on oral forms of supplementation.
There is evidence that leucine-rich diets may induce taste
aversion in rodents, at least temporarily [22,38]. Besides, in
excess leucine can be toxic [52]. To avoid possible interference
of leucine in the food palatability, we decided to supplement
leucine in the drinking water, which resulted in no changes in
food intake either in genetically obese mice or in wild-type
mice. The limitation is the relatively low solubility of leucine in
water and the fact that leucine supplementation will be linked
with water ingestion. Despite that, we were able to increase
daily leucine intake by up to 3-fold compared to control
animals. It is worth mentioning that the increase in leucine
intake attained by providing it in the drinking water was higher
or equivalent to the supplementation dose used in several
previously published studies that showed significant effects of
leucine [19,21,24-26,31,32,35,36,47,49,50].
The studies that found changes in food intake mostly
provided leucine supplementation through the diet [22,23,38].
In one study, leucine-induced taste aversion was observed only
on the first day of supplementation [22]. However, Koch et al.
[38] found that dietary leucine supplementation reduced the
food intake by inducing taste aversion, whereas leucine
Figure 3.  Oral Leucine supplementation acutely increased food intake.  A. Oral gavage of a leucine solution increased the 24
h food intake (Day 3 and Day 4) compared to the days when the animals received gavage of water (Day 1 and Day 2). B. No
changes in body weight were observed among the experimental days. *, significantly different (P < 0.05) from D1 and D2 (gavage of
water).
doi: 10.1371/journal.pone.0084094.g003
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supplementation in the drinking water caused no effects on
food intake. In addition, only i.c.v. administration of leucine
reduced food intake, whereas gavage, subcutaneous or
intraperitoneal infusions caused no changes in feeding
behavior [38]. Because dietary leucine supplementation may
have this confounder, it is also important that future studies
perform the required controls to rule out possible effects of
leucine on food intake through influencing taste aversion or
food palatability.
Previous studies found that the central infusion of leucine
causes p70S6K phosphorylation in brain areas related to the
regulation of food intake, including the ARH, PVH, and NTS,
but not in the VMH, zona incerta, hippocampus and cerebral
cortex [22,30,44]. In addition, the infusion of leucine in the
mediobasal hypothalamus not only induces Fos expression in
the ARH but also in areas outside the injection site, such as the
PVH and NTS [39]. We failed to detect significant changes in
Fos expression in the PVH, ARH or NTS. Another study [53]
identified amino acids that are able to induce Fos expression in
the hypothalamus. The authors found that the nonessential
amino acid asparagine induces Fos expression in orexin
neurons, which are involved in the regulation of food intake,
whereas leucine does not [53]. We observed a significant
increase in Fos expression only in the AP. The AP is
considered an important area for chemoreception, both in
detecting toxins and controlling nausea and vomiting. Lesions
of AP prevent taste-aversion conditioning after administration
of lithium chloride [54,55] or other substances [56]. Therefore,
the AP may be involved in the brain´s ability to sense leucine
intake.
It has long been known that variations in leucine availability
induce changes in the expression and/or activity of enzymes
that metabolize BCAA [57-60]. Much less is known about the
influence of leucine supplementation on the hypothalamic
expression of these enzymes. Some authors suggest that the
high expression of the cytosolic form of BCAT in the brain plays
a role in the synthesis of amino acid neurotransmitters (e.g.,
glutamate and GABA) by transferring the nitrogen group from
BCAA to neurotransmitter precursors [61]. Furthermore,
cytosolic BCAT may also be involved in the ability of the brain
to sense the availability of amino acids [61]. Regarding our
results, we observed an increased expression of BCAT1,
BCAT2 and BCKDK in the groups supplemented with leucine,
particularly in mice consuming the HFD. The increased
expression of the enzymes that metabolize BCAA in leucine-
supplemented animals is in accordance with the fact that the
body must prevent excessive increases in circulating leucine
levels, lest it cause toxic effects. BCAT2-knockout mice display
very high levels of BCAA and a lean phenotype which is
associated with elevated energy expenditure [62]. Interestingly,
BCAT2-knockout mice have increased food intake, most likely
as a compensatory mechanism for the higher energy
expenditure [62]. In accordance, other studies also observed
increased energy expenditure in animals supplemented with
leucine [21,25], sometimes associated with increased food
intake [21]. So, it is possible that the increased food intake
observed after acute administration of leucine in our study was
caused by compensatory mechanisms seeking to reestablish
the energy balance. Leucine supplementation did not affect the
expression of genes involved in the regulation of the energy
balance in mice consuming a low-fat diet. However, we
observed an increased expression of the orexigenic NPY in
diet-induced obese mice, at the same time they exhibited an
increased expression of the anorexigenic CRH. The reasons
for this particular pattern of hypothalamic gene expression are
unknown, but it may also reflect an attempt of the organism to
defend the energy homeostasis by balancing orexigenic and
anorexigenic neuronal pathways. In the long-term, the resulting
consequence may be the lack of changes in food intake as
observed in our study. Lastly, it is important to consider that
leucine supplementation may produce significant effects on
body metabolism independently of changes in the food intake.
Figure 4.  Chronic leucine supplementation did not change the food intake and water ingestion of ob/ob mice.  The food
intake and water ingestion of ob/ob mice (n = 7) were assessed for 20 consecutive days. During the first 10 days, the mice received
water to drink (H2O, white bar), followed by 10 days of leucine supplementation in the drinking water (Leucine, black bar).
doi: 10.1371/journal.pone.0084094.g004
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Figure 5.  Body weight, adiposity and food intake were not affected by chronic leucine supplementation.  Body weight (A),
mass of subcutaneous (SC), perigonadal (PG) and retroperitoneal (RP) fat pads (B-C), food intake (D-E, G-H) and water
consumption (F, I) in mice receiving low- and high-fat diets of control and leucine groups (n = 9-10 per group). *, significantly
different (P < 0.05) from control group.
doi: 10.1371/journal.pone.0084094.g005
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These effects can be observed in studies that found reductions
in adiposity in animals supplemented with leucine, even in the
absence of changes in food intake [19-21,24,25,31,37].
In summary, three sets of experiments using different
methods (activation of intracellular pathways, induction of Fos
protein and analysis of gene expression) demonstrated that the
brain possesses mechanisms allowing it to detect changes in
the availability of leucine from oral intake. Thus, leucine, as
well as glucose and lipids [3-7], can be sensed by the brain.
We also suggest that the AP is a putative area involved in the
brain’s leucine chemoreception. Despite the fact the brain is
able to sense leucine, chronic oral leucine supplementation (in
the drinking water) does not produce changes in the food
intake, nor does it cause an anorectic pattern of gene
expression in the hypothalamus. Although future studies should
directly assess the consequences of leucine supplementation
in humans, our results question the possible efficacy of leucine
supplementation as an appetite suppressant to treat obesity.
Materials and Methods
Animals
The mice used in the experiments were maintained under
standard conditions of light (12 h light/dark cycle; lights on 8:00
am), temperature (22 ± 2 °C) and relative humidity (55 ± 15%).
All animal procedures were approved by the Ethics Committee
on the Use of Animals of the Institute of Biomedical Sciences,
University of São Paulo, and were performed according to the
ethical guidelines adopted by the Brazilian College of Animal
Experimentation.
Experiment 1
Single-housed 10-week-old C57BL/6 male mice were daily
habituated to receive gavage for one week. Then, mice were
fasted overnight and at 9:00 am received an oral gavage
administration of 0.5 mL of water (control group, n = 9) or 0.15
м l-leucine (Synth, Brazil) solution (leucine group, n = 9). The
chosen dose of l-leucine (0.15 м or 1.967% wt/vol) is near to its
limit of solubility in water. Previous studies used this same
dose in the drinking water [26] or slightly lower amounts
(1.5-1.7% wt/vol) [21,24,25,35,38]. The mice were euthanized
by decapitation 90 min after the oral gavage, and the
hypothalami were quickly collected for western blot analysis.
To dissect the hypothalamus, we defined its limits as follows:
rostro-caudal, 1 mm anterior to the optic chiasm and
immediately posterior to the mammillary bodies; lateral, defined
by the optic tract; and superior, the dorsal limit of the third
ventricle.
Experiment 2
Single-housed 10-week-old C57BL/6 mice were habituated
daily to handling and to receiving oral gavage for one week to
minimize unspecific Fos expression. After that, mice were
fasted for 4 h, followed by an oral gavage administration of 0.5
mL of water (control group, n = 10) or 0.15 м L-leucine solution
(leucine group, n = 9) at 1:00 pm. After 3 h, mice were deeply
anesthetized and perfused transcardially with saline followed
by a 4% formaldehyde solution (150 mL each mouse). Brains
were collected and post-fixed in the same fixative for 2 h and
cryoprotected overnight at 4 °C in 0.1 м phosphate-buffered
saline (PBS), pH 7.4, containing 20% sucrose. Brains were cut
(30-µm sections) in the frontal plane using a freezing
microtome. Four series were collected in antifreeze solution
Figure 6.  Hypothalamic mRNA expression of genes involved in the BCAA metabolism and energy balance
regulation.  Gene expression was assessed in mice receiving a low-fat diet (A, n = 10 per group) or a high-fat diet (B, n = 9-10 per
group). *, significantly different (P < 0.05) from control group. †, P = 0.0532 versus control group.
doi: 10.1371/journal.pone.0084094.g006
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and stored at -20 °C. The time chosen to perfuse the mice after
the oral gavage of leucine to detect Fos immunoreactivity (Fos-
ir) was based on previous studies [53].
Experiment 3
Single-housed 10-week-old C57BL/6 male mice (n = 20)
were habituated daily to handling and to receiving oral gavage
(0.5 mL of water) for one week. Then, we assessed for 4
consecutive days their 24 h food intake and body weight. In the
first 2 days, mice received an oral gavage administration of 0.5
mL of water. In the next 2 days, they received an oral gavage
administration of 0.15 м L-leucine solution. The gavage took
place 3 hours before lights off. We assessed whether leucine
supplementation acutely affect the food intake, weight gain and
body weight of mice in comparison with the days the mice
received water.
Experiment 4
Ten-week-old C57BL/6 leptin-deficient (ob/ob) mice (n = 7;
initial body weight: 39.6 ± 0.5 g) were acclimated to single
housing for 1 week. After that, their food intake and water
ingestion were assessed daily for 20 consecutive days. In the
first 10 days of the experiment, the mice received water to
drink. In the remaining days, the contents of the drinking bottle
were replaced with a 0.15 м L-leucine solution. During the
entire experiment, the mice had ad libitum access to a regular
rodent chow diet (Quimtia, Nuvilab CR-1, Brazil). The objective
of this experiment was to assess whether leucine
supplementation changes the food intake in comparison to the
data collected when the mice received only water to drink. The
purpose in using the same animal as reference (control) was to
minimize interindividual variability in assessing the effects of
leucine on food intake. Therefore, each mouse acted as its own
control.
Experiment 5
Eight-week-old C57BL/6 male mice (n = 39) were distributed
into two groups according to diet: low-fat regular rodent chow
diet (Quimtia, Nuvilab CR-1, Brazil; 2.99 kcal/g; 9.4% calories
from fat) or a high-fat diet (PragSoluções, Brazil; 5.31 kcal/g,
58% calories from fat). After 2 months, each group was
redistributed into two more groups: control and leucine groups.
The mice were kept on their original diets, but the leucine
groups received a 0.15 м leucine solution in the drinking water,
whereas the control groups had water to drink. During the
experiment, the mice had ad libitum access to their
experimental diets and drinking bottle and we assessed their
food intake, water ingestion and body weight 3 times per week.
After 6 weeks of supplementation, the mice were fasted for 4 h
and euthanized by decapitation. The hypothalami were
dissected as previously described and frozen at -80 °C for
gene expression analysis. Serum corticosterone levels were
assessed by ELISA (Cayman Chemical).
Western Blot
Immediately after collection, the hypothalami were
homogenized in RIPA buffer (Sigma) containing a cocktail of
protease and phosphatase inhibitors (1:100, Sigma), then
resolved in 10% SDS-PAGE gel and finally transferred to a
nitrocellulose membrane. After blocking the membrane with 5%
BSA, the membrane was incubated overnight at 4°C using
commercially available antibodies (phospho-p70S6K, Cell
Signaling, #9205, 1:1,000; and α-actinin, Santa Cruz, H-300,
1:1,000). Next, we incubated the membrane for 45 min in
IRDye 800CW secondary antibody (1:10,000, Li-COR).
Proteins were visualized and analyzed using the Li-COR
Odyssey system (Li-COR) and phospho-p70S6K expression
was normalized to α-actinin expression.
Immunohistochemistry
The immunohistochemistry protocol followed has been
previously described [63]. Briefly, brain sections were rinsed in
0.02 м potassium PBS, pH 7.4 (KPBS), followed by a
pretreatment with 0.3% hydrogen peroxide for 30 min. After
rinses in KPBS, sections were blocked in 3% normal donkey
serum for 1 h, followed by incubation in anti-Fos polyclonal
primary antibody raised in rabbit (1:20,000, Ab5, Millipore) for
48 h. Subsequently, sections were incubated for 1 h in biotin-
conjugated IgG donkey anti-rabbit (1:1,000, Jackson
Laboratories) and for 1 h in avidin-biotin complex (1:500,
Vector Labs). The sections were then submitted to a 3-5 min
immunoperoxidase reaction with 0.03% hydrogen peroxide
dissolved in 0.1 м acetate buffer, pH 6.0, using
diaminobenzidine tetrahydrochloride (DAB; Sigma) and 0.5%
nickel sulfate as chromogens. Sections were mounted onto
gelatin-coated slides, dried overnight, dehydrated in ethanol,
cleared in xylene and coverslipped with DPX Mountant for
histology (Sigma-Aldrich). Fos-ir was analyzed in the PVH,
ARH, VMH, LHA, DMH, NTS and AP. Nuclear boundaries were
determined using a mouse brain atlas as reference [64]. We
counted the number of cells expressing a dark-brown/black
nuclear staining in one side of a representative rostral-to-
caudal level of each area. A researcher with experience in
counting Fos immunoreactivity and blinded to the experimental
groups was designed to do all the counting. The ImageJ Cell
Counter tool was used to mark each counted cell avoiding
double counting. Photomicrographs were acquired with a Zeiss
Axiocam HRc camera adapted to a Zeiss Axioimager A1
microscope (Zeiss, Munich, Germany). Images were digitalized
using the Axiovision software (Zeiss). Photoshop CS5 (Adobe)
image-editing software was used to combine photomicrographs
into plates. Only sharpness, contrast and brightness were
adjusted.
Relative Gene Expression (qPCR)
Total RNA were extracted with TRIzol® reagent (Invitrogen)
according to the manufacturer’s instructions. Assessment of
RNA quantity and quality was performed with an Epoch
Microplate Spectrophotometer (Biotek®). Total RNA was
incubated in DNase I RNase-free (Roche Applied Science).
Reverse transcription was performed with 2 µg of total RNA
with SuperScript® II Reverse Transcriptase (Invitrogen) and
random primers p(dN)6 (Roche Applied Science). Real-time
polymerase chain reaction (qPCR) was performed using the
7500 Fast Real-Time PCR System (Applied Biosystems®) on
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duplicates of each cDNA and optimized using Power SYBR
Green PCR Master Mix or TaqMan® Gene Expression Master
Mix (both from Applied Biosystems®). Speciﬁc primers were
designed for each target gene according to sequences taken
from GenBank or the literature (Table S1). Melt curve analysis
was conducted to validate the speciﬁcity of the primers.
Relative quantification of mRNA was calculated by 2-ΔΔCt [65].
Data were normalized to β-actin expression and reported as
fold changes compared to values obtained from the control
group (set at 1.0).
Statistical analysis
For statistical analysis of the data from Experiments 1, 2 and
5, we used the unpaired two-tailed Student’s t-test. In
Experiment 3, data were compared using the repeated
measures ANOVA followed by Newman-Keuls posttest. In
Experiment 4, data were compared using the paired two-tailed
Student’s t-test. A P value of <0.05 was considered significant
in all analyses. The results are expressed as the mean ± SEM.
Statistical analysis was performed using GraphPad Prism
software.
Supporting Information
Figure S1.  Serum corticosterone levels. Corticosterone
levels of control and leucine groups (n = 8-10 per group) were
compared to values obtained from mice that were subjected to
psychosocial stress (3 days in individual cages followed by
regrouping for 30 min; n = 4) or prolonged fasting (n = 8). *,
significantly different (P < 0.05) from control and leucine
groups.
(TIF)
Table S1.  Primer sequences.
(DOCX)
Acknowledgements
We thank Lucas C. Pantaleão, José Luiz dos Santos and Ana
Maria P. Campos for the technical assistance.
Author Contributions
Conceived and designed the experiments: TTZ JD. Performed
the experiments: TTZ JABP ICF JD. Analyzed the data: TTZ
JABP JD. Contributed reagents/materials/analysis tools: JT.
Wrote the manuscript: JD.
References
1. Myers MG Jr., Olson DP (2012) Central nervous system control of
metabolism. Nature 491: 357-363. doi:10.1038/nature11705. PubMed:
23151578.
2. Williams KW, Elmquist JK (2012) From neuroanatomy to behavior:
central integration of peripheral signals regulating feeding behavior. Nat
Neurosci 15: 1350-1355. doi:10.1038/nn.3217. PubMed: 23007190.
3. Parton LE, Ye CP, Coppari R, Enriori PJ, Choi B et al. (2007) Glucose
sensing by POMC neurons regulates glucose homeostasis and is
impaired in obesity. Nature 449: 228-232. doi:10.1038/nature06098.
PubMed: 17728716.
4. Levin BE, Dunn-Meynell AA, Routh VH (1999) Brain glucose sensing
and body energy homeostasis: role in obesity and diabetes. Am J
Physiol 276: R1223-R1231. PubMed: 10233011.
5. Miki T, Liss B, Minami K, Shiuchi T, Saraya A et al. (2001) ATP-
sensitive K+ channels in the hypothalamus are essential for the
maintenance of glucose homeostasis. Nat Neurosci 4: 507-512.
PubMed: 11319559.
6. Lam TK, Pocai A, Gutierrez-Juarez R, Obici S, Bryan J et al. (2005)
Hypothalamic sensing of circulating fatty acids is required for glucose
homeostasis. Nat Med 11: 320-327. doi:10.1038/nm1201. PubMed:
15735652.
7. Yue Jessica TY, Lam Tony KT (2012) Lipid Sensing and Insulin
Resistance in the Brain. Cell Metab 15: 646-655. doi:10.1016/j.cmet.
2012.01.013. PubMed: 22560217.
8. Anthony JC, Anthony TG, Kimball SR, Vary TC, Jefferson LS (2000)
Orally administered leucine stimulates protein synthesis in skeletal
muscle of postabsorptive rats in association with increased eIF4F
formation. J Nutr 130: 139-145. PubMed: 10720160.
9. Garlick PJ (2005) The role of leucine in the regulation of protein
metabolism. J Nutr 135: 1553S-1556S. PubMed: 15930468.
10. Anthony JC, Yoshizawa F, Anthony TG, Vary TC, Jefferson LS et al.
(2000) Leucine stimulates translation initiation in skeletal muscle of
postabsorptive rats via a rapamycin-sensitive pathway. J Nutr 130:
2413-2419. PubMed: 11015466.
11. Anthony JC, Anthony TG, Kimball SR, Jefferson LS (2001) Signaling
pathways involved in translational control of protein synthesis in
skeletal muscle by leucine. J Nutr 131: 856S-860S. PubMed:
11238774.
12. Anthony TG, Anthony JC, Yoshizawa F, Kimball SR, Jefferson LS
(2001) Oral administration of leucine stimulates ribosomal protein
mRNA translation but not global rates of protein synthesis in the liver of
rats. J Nutr 131: 1171-1176. PubMed: 11285321.
13. Dardevet D, Sornet C, Bayle G, Prugnaud J, Pouyet C et al. (2002)
Postprandial stimulation of muscle protein synthesis in old rats can be
restored by a leucine-supplemented meal. J Nutr 132: 95-100.
PubMed: 11773514.
14. Lynch CJ, Hutson SM, Patson BJ, Vaval A, Vary TC (2002) Tissue-
specific effects of chronic dietary leucine and norleucine
supplementation on protein synthesis in rats. Am J Physiol Endocrinol
Metab 283: E824-E835. PubMed: 12217901.
15. Lynch CJ, Halle B, Fujii H, Vary TC, Wallin R et al. (2003) Potential role
of leucine metabolism in the leucine-signaling pathway involving
mTOR. Am J Physiol Endocrinol Metab 285: E854-E863. PubMed:
12812918.
16. Han Jung M, Jeong Seung J, Park Min C, Kim G, Kwon Nam H et al.
(2012) Leucyl-tRNA Synthetase Is an Intracellular Leucine Sensor for
the mTORC1-Signaling Pathway. Cell 149: 410-424. doi:10.1016/j.cell.
2012.02.044. PubMed: 22424946.
17. Layman DK (2003) The role of leucine in weight loss diets and glucose
homeostasis. J Nutr 133: 261S-267S. PubMed: 12514305.
18. Layman DK, Walker DA (2006) Potential importance of leucine in
treatment of obesity and the metabolic syndrome. J Nutr 136:
319S-323S. PubMed: 16365106.
19. Donato J Jr., Pedrosa RG, Cruzat VF, Pires IS, Tirapegui J (2006)
Effects of leucine supplementation on the body composition and protein
status of rats submitted to food restriction. Nutrition 22: 520-527. doi:
10.1016/j.nut.2005.12.008. PubMed: 16600817.
20. Vianna D, Resende GFT, Torres-Leal FL, Pantaleão LC, Donato J Jr et
al. (2012) Long-term leucine supplementation reduces fat mass gain
without changing body protein status of aging rats. Nutrition 28:
182-189. doi:10.1016/j.nut.2011.04.004. PubMed: 21872432.
21. Zhang Y, Guo K, LeBlanc RE, Loh D, Schwartz GJ et al. (2007)
Increasing dietary leucine intake reduces diet-induced obesity and
improves glucose and cholesterol metabolism in mice via
multimechanisms. Diabetes 56: 1647-1654. doi:10.2337/db07-0123.
PubMed: 17360978.
Oral Leucine Does Not Induce Anorectic Behavior
PLOS ONE | www.plosone.org 11 December 2013 | Volume 8 | Issue 12 | e84094
22. Ropelle ER, Pauli JR, Fernandes MFA, Rocco SA, Marin RM et al.
(2008) A Central Role for Neuronal AMP-Activated Protein Kinase
(AMPK) and Mammalian Target of Rapamycin (mTOR) in High-Protein
Diet-Induced Weight Loss. Diabetes 57: 594-605. doi:10.2337/
db07-0573. PubMed: 18057094.
23. Freudenberg A, Petzke KJ, Klaus S (2012) Comparison of high-protein
diets and leucine supplementation in the prevention of metabolic
syndrome and related disorders in mice. J Nutr Biochem 23:
1524-1530. doi:10.1016/j.jnutbio.2011.10.005. PubMed: 22405695.
24. Macotela Y, Emanuelli B, Bång AM, Espinoza DO, Boucher J et al.
(2011) Dietary Leucine - An Environmental Modifier of Insulin
Resistance Acting on Multiple Levels of Metabolism. PLOS ONE 6:
e21187. doi:10.1371/journal.pone.0021187. PubMed: 21731668.
25. Binder E, Bermudez-Silva FJ, Andre C, Elie M, Romero-Zerbo SY et al.
(2013) Leucine Supplementation Protects from Insulin Resistance by
Regulating Adiposity Levels. PLOS ONE 8: e74705. doi:10.1371/
journal.pone.0074705. PubMed: 24086364.
26. Nairizi A, She P, Vary TC, Lynch CJ (2009) Leucine Supplementation
of Drinking Water Does Not Alter Susceptibility to Diet-Induced Obesity
in Mice. J Nutr 139: 715-719. doi:10.3945/jn.108.100081. PubMed:
19244380.
27. Torres-Leal FL, Fonseca-Alaniz MH, Teodoro GF, de Capitani MD,
Vianna D et al. (2011) Leucine supplementation improves adiponectin
and total cholesterol concentrations despite the lack of changes in
adiposity or glucose homeostasis in rats previously exposed to a high-
fat diet. Nutr Metab (Lond) 8: 62. PubMed: 21899736.
28. Zemel MB, Bruckbauer A (2012) Effects of a Leucine and Pyridoxine-
Containing Nutraceutical on Fat Oxidation, and Oxidative and
Inflammatory Stress in Overweight and Obese Subjects. Nutrients 4:
529-541. doi:10.3390/nu4060529. PubMed: 22822451.
29. Verhoeven S, Vanschoonbeek K, Verdijk LB, Koopman R, Wodzig WK
et al. (2009) Long-term leucine supplementation does not increase
muscle mass or strength in healthy elderly men. Am J Clin Nutr 89:
1468-1475. doi:10.3945/ajcn.2008.26668. PubMed: 19321567.
30. Cota D, Proulx K, Smith KA, Kozma SC, Thomas G et al. (2006)
Hypothalamic mTOR signaling regulates food intake. Science 312:
927-930. doi:10.1126/science.1124147. PubMed: 16690869.
31. Donato J Jr., Pedrosa RG, de Araújo JA Jr., Pires IS, Tirapegui J
(2007) Effects of leucine and phenylalanine supplementation during
intermittent periods of food restriction and refeeding in adult rats. Life
Sci 81: 31-39. doi:10.1016/j.lfs.2007.04.015. PubMed: 17512018.
32. Pedrosa RG, Donato J Jr., Pires ISO, Tirapegui J (2010) Leucine
supplementation favors liver protein status but does not reduce body fat
in rats during 1 week of food restriction. Applied Physiology, Nutrition,
and Metabolism 35: 180-183. doi:10.1139/H09-132. PubMed:
20383228.
33. Teodoro GFR, Vianna D, Torres-Leal FL, Pantaleão LC, Matos-Neto
EM et al. (2012) Leucine Is Essential for Attenuating Fetal Growth
Restriction Caused by a Protein-Restricted Diet in Rats. J Nutr 142:
924-930. doi:10.3945/jn.111.146266. PubMed: 22457392.
34. Zeanandin G, Balage M, Schneider SM, Dupont J, Hébuterne X et al.
(2012) Differential effect of long-term leucine supplementation on
skeletal muscle and adipose tissue in old rats: an insulin signaling
pathway approach. Age 34: 371-387. doi:10.1007/s11357-011-9246-0.
PubMed: 21472380.
35. Chen H, Simar D, Ting JHY, Erkelens JRS, Morris MJ (2012) Leucine
Improves Glucose and Lipid Status in Offspring from Obese Dams,
Dependent on Diet Type, but not Caloric Intake. J Neuroendocrinol 24:
1356-1364. doi:10.1111/j.1365-2826.2012.02339.x. PubMed:
22612562.
36. López N, Sánchez J, Picó C, Palou A, Serra F (2010) Dietary l-leucine
supplementation of lactating rats results in a tendency to increase
lean/fat ratio associated to lower orexigenic neuropeptide expression in
hypothalamus. Peptides 31: 1361-1367. doi:10.1016/j.peptides.
2010.03.028. PubMed: 20347902.
37. Li X, Wang X, Liu R, Ma Y, Guo H et al. (2013) Chronic leucine
supplementation increases body weight and insulin sensitivity in rats on
high-fat diet likely by promoting insulin signaling in insulin-target
tissues. Mol Nutr Food Res 57: 1067-1079. doi:10.1002/mnfr.
201200311. PubMed: 23404947.
38. Koch C, Göddeke S, Krüger M, Tups A (2012) Effect of central and
peripheral leucine on energy metabolism in the Djungarian hamster
(Phodopus sungorus ). Journal of Comparative Physiology B,
Biochemical, Systemic, and Environmental Physiology: 1-8.
39. Blouet C, Jo Y-H, Li X, Schwartz GJ (2009) Mediobasal Hypothalamic
Leucine Sensing Regulates Food Intake through Activation of a
Hypothalamus–Brainstem Circuit. Journal of Neuroscience 29:
8302-8311. doi:10.1523/JNEUROSCI.1668-09.2009. PubMed:
19571121.
40. Reiter AK, Anthony TG, Anthony JC, Jefferson LS, Kimball SR (2004)
The mTOR signaling pathway mediates control of ribosomal protein
mRNA translation in rat liver. Int J Biochem Cell Biol 36: 2169-2179.
doi:10.1016/j.biocel.2004.04.004. PubMed: 15313464.
41. Lynch CJ, Patson BJ, Anthony J, Vaval A, Jefferson LS et al. (2002)
Leucine is a direct-acting nutrient signal that regulates protein synthesis
in adipose tissue. Am J Physiol Endocrinol Metab 283: E503-E513.
PubMed: 12169444.
42. Hoffman GE, Lyo D (2002) Anatomical markers of activity in
neuroendocrine systems: are we all 'fos-ed out'? J Neuroendocrinol 14:
259-268. doi:10.1046/j.1365-2826.2002.00775.x. PubMed: 11963822.
43. Sweatt AJ, Wood M, Suryawan A, Wallin R, Willingham MC et al.
(2004) Branched-chain amino acid catabolism: unique segregation of
pathway enzymes in organ systems and peripheral nerves. Am J
Physiol Endocrinol Metab 286: E64-E76. PubMed: 12965870.
44. Blouet C, Schwartz Gary J (2012) Brainstem Nutrient Sensing in the
Nucleus of the Solitary Tract Inhibits Feeding. Cell Metab 16: 579-587.
doi:10.1016/j.cmet.2012.10.003. PubMed: 23123165.
45. Rieu I, Sornet C, Bayle G, Prugnaud J, Pouyet C et al. (2003) Leucine-
supplemented meal feeding for ten days beneficially affects
postprandial muscle protein synthesis in old rats. J Nutr 133:
1198-1205. PubMed: 12672943.
46. Magne H, Savary-Auzeloux I, Migné C, Peyron M-A, Combaret L et al.
(2012) Contrarily to whey and high protein diets, dietary free leucine
supplementation cannot reverse the lack of recovery of muscle mass
after prolonged immobilization during ageing. J Physiol 590:
2035-2049. PubMed: 22351629.
47. Sugawara T, Yoshiwaki I, Nishizawa N, Nagasawa T (2007)
Supplemantation with dietary leucine to a protein-deficient diet
supresses myofibrillar protein degradation in rats. J Nutr Sci Vitaminol
(Tokyo) 53: 552-555. doi:10.3177/jnsv.53.552. PubMed: 18202546.
48. Freudenberg A, Petzke KJ, Klaus S (2013) Dietary L: -leucine and L: -
alanine supplementation have similar acute effects in the prevention of
high-fat diet-induced obesity. Amino Acids 44: 519-528. PubMed:
22847780.
49. Li H, Xu M, Lee J, He C, Xie Z (2012) Leucine Supplementation
Increases SIRT1 Expression and Prevents Mitochondrial Dysfunction
and Metabolic Disorders in High Fat Diet-induced Obese Mice. Am J
Physiol Endocrinol Metab 303: E1234-E1244. doi:10.1152/ajpendo.
00198.2012. PubMed: 22967499.
50. Guo K, Yu YH, Hou J, Zhang Y (2010) Chronic leucine
supplementation improves glycemic control in etiologically distinct
mouse models of obesity and diabetes mellitus. Nutr Metab (Lond) 7:
57. doi:10.1186/1743-7075-7-57. PubMed: 20624298.
51. Drgonova J, Jacobsson JA, Han JC, Yanovski JA, Fredriksson R et al.
(2013) Involvement of the Neutral Amino Acid Transporter SLC6A15
and Leucine in Obesity-Related Phenotypes. PLOS ONE 8: e68245.
doi:10.1371/journal.pone.0068245. PubMed: 24023709.
52. Imamura W, Yoshimura R, Takai M, Yamamura J, Kanamoto R et al.
(2013) Adverse effects of excessive leucine intake depend on dietary
protein intake: a transcriptomic analysis to identify useful biomarkers. J
Nutr Sci Vitaminol (Tokyo) 59: 45-55. doi:10.3177/jnsv.59.45. PubMed:
23535539.
53. Karnani Mahesh M, Apergis-Schoute J, Adamantidis A, Jensen Lise T,
de Lecea L et al. (2011) Activation of Central Orexin/Hypocretin
Neurons by Dietary Amino Acids. Neuron 72: 616-629. doi:10.1016/
j.neuron.2011.08.027. PubMed: 22099463.
54. Bernstein IL, Chavez M, Allen D, Taylor EM (1992) Area postrema
mediation of physiological and behavioral effects of lithium chloride in
the rat. Brain Res 575: 132-137. doi:10.1016/0006-8993(92)90432-9.
PubMed: 1324085.
55. Ritter S, McGlone JJ, Kelley KW (1980) Absence of lithium-induced
taste aversion after area postrema lesion. Brain Res 201: 501-506. doi:
10.1016/0006-8993(80)91061-6. PubMed: 7417860.
56. Coil JD, Norgren R (1981) Taste aversions conditioned with
intravenous copper sulfate: Attenuation by ablation of the area
postrema. Brain Res 212: 425-433. doi:
10.1016/0006-8993(81)90474-1. PubMed: 7225877.
57. Paxton R, Harris RA (1984) Regulation of branched-chain alpha-
ketoacid dehydrogenase kinase. Arch Biochem Biophys 231: 48-57.
doi:10.1016/0003-9861(84)90361-8. PubMed: 6721501.
58. Harris RA, Joshi M, Jeoung NH (2004) Mechanisms responsible for
regulation of branched-chain amino acid catabolism. Biochem Biophys
Res Commun 313: 391-396. doi:10.1016/j.bbrc.2003.11.007. PubMed:
14684174.
59. She P, Van Horn C, Reid T, Hutson SM, Cooney RN et al. (2007)
Obesity-related elevations in plasma leucine are associated with
alterations in enzymes involved in branched-chain amino acid
Oral Leucine Does Not Induce Anorectic Behavior
PLOS ONE | www.plosone.org 12 December 2013 | Volume 8 | Issue 12 | e84094
metabolism. Am J Physiol Endocrinol Metab 293: E1552-E1563. doi:
10.1152/ajpendo.00134.2007. PubMed: 17925455.
60. Newgard CB, An J, Bain JR, Muehlbauer MJ, Stevens RD et al. (2009)
A Branched-Chain Amino Acid-Related Metabolic Signature that
Differentiates Obese and Lean Humans and Contributes to Insulin
Resistance. Cell Metab 9: 311-326. doi:10.1016/j.cmet.2009.02.002.
PubMed: 19356713.
61. García-Espinosa MA, Wallin R, Hutson SM, Sweatt AJ (2007)
Widespread neuronal expression of branched-chain aminotransferase
in the CNS: implications for leucine/glutamate metabolism and for
signaling by amino acids. J Neurochem 100: 1458-1468. PubMed:
17348860.
62. She P, Reid TM, Bronson SK, Vary TC, Hajnal A et al. (2007)
Disruption of BCATm in mice leads to increased energy expenditure
associated with the activation of a futile protein turnover cycle. Cell
Metab 6: 181-194. doi:10.1016/j.cmet.2007.08.003. PubMed:
17767905.
63. Donato J Jr., Cavalcante JC, Silva RJ, Teixeira AS, Bittencourt JC et al.
(2010) Male and female odors induce Fos expression in chemically
defined neuronal population. Physiol Behav 99: 67-77. doi:10.1016/
j.physbeh.2009.10.012. PubMed: 19857504.
64. Paxinos G, Franklin KBJ (2001) The Mouse Brain in Stereotaxic
Coordinates. San Diego: Academic Press.
65. Livak KJ, Schmittgen TD (2001) Analysis of Relative Gene Expression
Data Using Real-Time Quantitative PCR and the 2-ΔΔCT Method.
Methods 25: 402-408. doi:10.1006/meth.2001.1262. PubMed:
11846609.
Oral Leucine Does Not Induce Anorectic Behavior
PLOS ONE | www.plosone.org 13 December 2013 | Volume 8 | Issue 12 | e84094
